Financial reports
10-Q
2019 Q3
Quarterly report
30 Oct 19
10-Q
2019 Q2
Quarterly report
24 Jul 19
10-Q
2019 Q1
Quarterly report
26 Apr 19
10-K
2018 FY
Annual report
27 Feb 19
10-Q
2018 Q3
Quarterly report
8 Nov 18
10-Q
2018 Q2
Quarterly report
2 Aug 18
10-Q
2018 Q1
Quarterly report
9 May 18
10-K
2017 FY
Annual report
1 Mar 18
10-Q
2017 Q3
Quarterly report
9 Nov 17
10-Q
2017 Q2
Quarterly report
9 Aug 17
Current reports
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
6 Jan 20
8-K
Entry into a Material Definitive Agreement
6 Jan 20
8-K
The Medicines Company Enters Into Definitive Agreement to be Acquired by Novartis AG for $9.7 billion
25 Nov 19
8-K
The Medicines Company Reports Third-Quarter 2019 Financial Results and Achievement of Major Milestones for Inclisiran
30 Oct 19
8-K
The Medicines Company Reports Second-Quarter 2019 Financial Results and Updates Clinical Development Program
24 Jul 19
8-K
The Medicines Company Announces Pricing of Public Offering of Common Stock
28 Jun 19
8-K
Submission of Matters to a Vote of Security Holders
5 Jun 19
8-K
The Medicines Company Reports First-Quarter 2019 Financial Results and Significant Progress with the Inclisiran Clinical Development Program
25 Apr 19
8-K
Departure of Directors or Certain Officers
18 Mar 19
8-K
The Medicines Company Reports Fourth-Quarter and Full Year 2018 Business and Financial Results
27 Feb 19
Registration and prospectus
15-12G
Securities registration termination
16 Jan 20
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Jan 20
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Jan 20
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Jan 20
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Jan 20
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Jan 20
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Jan 20
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Jan 20
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Jan 20
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Jan 20
Proxies
DEF 14A
Definitive proxy
29 Apr 19
DEF 14A
Definitive proxy
30 Apr 18
DEF 14A
Definitive proxy
26 Apr 17
DEF 14A
Definitive proxy
26 Apr 16
PRE 14A
Preliminary proxy
12 Apr 16
DEF 14A
Definitive proxy
30 Apr 15
PRE 14A
Preliminary proxy
17 Apr 15
DEF 14A
Definitive proxy
30 Apr 14
DEFA14A
Additional proxy soliciting materials
20 May 13
DEF 14A
Definitive proxy
29 Apr 13
Other
EFFECT
Notice of effectiveness
10 Jan 20
EFFECT
Notice of effectiveness
10 Jan 20
EFFECT
Notice of effectiveness
10 Jan 20
CT ORDER
Confidential treatment order
26 Nov 19
CT ORDER
Confidential treatment order
19 Mar 19
CT ORDER
Confidential treatment order
27 Aug 18
SD
Conflict minerals disclosure
30 May 18
CT ORDER
Confidential treatment order
26 Mar 18
CT ORDER
Confidential treatment order
6 Dec 17
UPLOAD
Letter from SEC
11 Oct 17
Ownership
SC 13G/A
Medicines Co /De
14 Feb 20
SC 13G/A
Beneficial ownership report (amended)
12 Feb 20
SC 13G/A
Beneficial ownership report (amended)
12 Feb 20
SC 13G/A
Beneficial ownership report (amended)
10 Feb 20
SC 13G/A
Beneficial ownership report (amended)
28 Jan 20
SC 13D/A
Medicines Co /De
7 Jan 20
SC 13G/A
Medicines Co /De
7 Jan 20
4
Peter Wijngaard
6 Jan 20
4
Christopher Visioli
6 Jan 20
4
Mark Timney
6 Jan 20